Dublin’s Vertigenius aims to transform delivery of care for vertigo sufferers and is already available in 20 US clinics, where the market opportunity is estimated at some $3bn.
Following a €2.1m fundraising round in 2024, Dublin medtech Vertigenius has closed a second funding round of $2.55m, led by Atlantic Bridge and supported by Enterprise Ireland, MedTech Syndicate, IRRUS Investments, Xcendra Ventures, Ascentifi, among others.
Originally founded by Dr Dara Meldrum in Trinity College Dublin, Vertigenius has developed a wearable sensor and app that can help monitor the treatment of vertigo at home.
The wearable head sensor medical device allows clinicians to track patients’ at-home treatment remotely, monitor progress and adjust prescribed treatment accordingly. In the US, clinics can access additional insurance reimbursement1 for remote monitoring of patients, which the company says opens up previously unavailable income streams.
Having attained FDA registration, Vertigenius launched in the US market in October 2025. The device is already being deployed in 20 clinics across 11 US states, with 3,000 patients having been treated. Vertigenius aims to use the new funding to further tap into this $3bn market which has more than 5,000 vestibular clinics.
It plans to further grow its US commercial team, and has already added two US sales directors. The investment will also fund hiring in clinical research, product R&D, quality assurance and regulatory affairs here in its Irish headquarters.
Over the next five years, Vertigenius also plans to expand further in Europe and enter other markets including Asia Pacific to transform the treatment of vertigo globally.
“By transforming real-time data into clinically relevant insights, providers can now proactively tailor treatments and significantly elevate the standard of patient care that they are providing,” said Mark Barry, CEO, Vertigenius.
“This investment marks an exciting new chapter for Vertigenius as we move into the world’s largest market for vestibular care. The early traction we have seen in the US validates both the clinical value of our platform and the commercial opportunity.”
“Vertigenius is addressing a significant gap in vestibular care in a multi-billion dollar market,” said Conor O’Sullivan, Investment Director, Atlantic Bridge. “The team has built a unique platform that is significantly enhancing the delivery of vestibular care by supporting clinicians and patients between visits, and we are excited to back their US expansion.”
Don’t miss out on the knowledge you need to succeed. Sign up for the Daily Brief, Silicon Republic’s digest of need-to-know sci-tech news.
